A wave of gene‑editing studies published this April shows that patients with severe blood disorders are finally seeing lasting, transfusion‑free lives. In China, a team led by Prof. Chen Jia (ShanghaiTech) and collaborators reported in *Nature* the results of a Phase 1 trial using a transformer base editor (tBE) to modify patients’ own CD34+ stem cells. Five β‑thalassemia patients received the edited cells (CS‑101) and, after a median 23‑month follow‑up, all stopped blood transfusions within three weeks. Hemoglobin levels rose to an average of 12.4 g/dL and fetal hemoglobin (HbF) stayed high, while engraftment times for neutrophils and platelets were rapid (16 and 25 days). No deaths, cancers, or unexpected side‑effects were reported. Across the Pacific, three NEJM papers described CRISPR‑Cas12a and base‑editing approaches (reni‑cel and risto‑cel) for sickle cell disease and transfusion‑dependent β‑thalassemia. In a multicenter Phase 1‑2 study, 27 of 28 sickle‑cell patients experienced no painful vaso‑occlusive crises after treatment, and hemoglobin normalized with a surge in HbF. A parallel β‑thalassemia trial showed rapid neutrophil recovery, sustained HbF increase, and complete transfusion independence. Another base‑editing trial (risto‑cel) confirmed durable HbF elevation and a drop in sickle hemoglobin. Together, these studies mark the first clinical successes of precise gene‑editing for anemia‑related disorders, offering a potential cure for tens of thousands of children born each year with β‑thalassemia or sickle cell disease.
Read moreChina’s drug regulator has fast‑tracked 13 innovative medicines to market so far in 2026, covering everything from cancer therapies to diabetes and cholesterol pills. Six of these are first‑in‑class drugs, meaning they work in ways no existing medicine does. One headline‑grabbing approval is BeiGene’s tarlatamab (branded Entedrig), the world’s first bispecific T‑cell engager that targets both DLL3 and CD3, now conditionally cleared for small‑cell lung cancer. The drug is being co‑developed and sold in China by BeiGene and U.S. giant Amgen. The approval surge reflects a broader shift: multinational firms are moving beyond simple licensing deals and forming deeper collaborations with Chinese innovators. Zai Lab, for example, is running a global Phase 3 trial of its own DLL3‑targeted ADC, Zocilurtatug, while supplying the drug to Amgen for joint development. In these models, Chinese companies keep full ownership of their molecules and share clinical expertise, creating a win‑win that speeds up patient access. China’s overseas licensing deals for innovative drugs topped $60 billion in the first quarter alone—almost half of the total expected for the whole year. Industry leaders say Chinese firms still need partners to build overseas sales teams, navigate foreign regulations and set up supply chains. The government’s latest work report also highlighted the push to expand commercial health‑insurance coverage for these cutting‑edge treatments, underscoring the country’s commitment to turning scientific breakthroughs into everyday medicines.
Read moreA wave of recent studies is reshaping treatment for nasopharyngeal carcinoma (NPC), offering fresh optimism for patients facing recurrence or metastasis. A large Phase 3 trial led by Fudan University and Zhejiang Cancer Hospital showed that adding the PD‑1 blocker camrelizumab to standard chemoradiotherapy markedly extended progression‑free survival (PFS) and cut the risk of distant spread in high‑risk NPC, with side‑effects remaining manageable. In parallel, the anti‑PD‑1 antibody penpulimab combined with chemotherapy also delivered a significant PFS benefit in a double‑blind study, though overall‑survival data are still maturing. A separate Phase III trial highlighted the 5‑year survival advantage of camrelizumab plus chemotherapy, reporting a 13.6% absolute increase in five‑year survival and rapid EBV‑DNA clearance as a predictive marker. Beyond immunotherapy, researchers uncovered a troubling role for the bacterium Fusobacterium nucleatum, which hijacks the host’s FadA‑RAB7A pathway to evade autophagy and foster drug resistance. Meanwhile, a lobaplatin‑based chemotherapy regimen proved just as effective as cisplatin for locally advanced NPC while sparing patients from hearing loss, kidney damage, and nerve toxicity. Finally, the novel Iz‑Blu (Izalertamab‑Blu) regimen showed strong activity in heavily pre‑treated metastatic NPC, and a quality‑of‑life study suggested that omitting traditional cisplatin from radiotherapy may preserve patients’ daily functioning. Together, these findings point to a future where targeted immunotherapy, smarter chemotherapy choices, and microbiome awareness could dramatically improve outcomes for NPC patients.
Read more